IL17A and triple-A syndrome: Oxidative stress is one of the major pathogenic factors of AAA, and a study proved riboflavin (vitamin B2), a kind of antioxidant, could prevent aneurysm formation in rat models (78), which suggests inhibiting oxidative stress by controlling IL-17 synthesis and activity of Th17 cells may be a potential therapeutic target for AAA patients.